BACKGROUND: Macrophages contribute to the progression and acute complications of atherosclerosis. Macrophage imaging may serve as a biomarker to identify subclinical inflamed lesions, to predict future risk, and to aid in the assessment of novel therapies. METHODS AND RESULTS: To test the hypothesis that nanoparticle-enhanced, high-resolution magnetic resonance imaging (MRI) can measure plaque macrophage accumulation, we used 3-T MRI with a macrophage-targeted superparamagnetic nanoparticle preparation (monocrystalline iron oxide nanoparticles-47 [MION-47]) in cholesterol-fed New Zealand White rabbits 6 months after balloon injury. In vivo MRI visualized thickened abdominal aortas on both T1- and T2-weighted spin-echo images (T1 spin echo, 20 axial slices per animal; T2 spin echo, 28 slices per animal). Seventy-two hours after MION-47 injection, aortas exhibited lower T2 signal intensity compared with before contrast imaging (signal intensity ratio, aortic wall/muscle: before, 1.44 ± 0.26 versus after, 0.95 ± 0.22; 164 slices; P<0.01), whereas T1 spin echo images showed no significant change. MRI on ex vivo specimens provided similar results. Histological studies colocalized iron accumulation with immunoreactive macrophages in atheromata. The magnitude of signal intensity reduction on T2 spin echo in vivo images further correlated with macrophage areas in situ (150 slices; r=0.73). Treatment with rosuvastatin for 3 months yielded diminished macrophage content (P<0.05) and reversed T2 signal intensity changes (P<0.005). Signal changes in rosuvastatin-treated rabbits correlated with reduced macrophage burden (r=0.73). In vitro validation studies showed concentration-dependent MION-47 uptake by human primary macrophages. CONCLUSION: The magnitude of T2 signal intensity reduction in high-resolution MRI after administration of superparamagnetic phagocytosable nanoparticles can assess macrophage burden in atheromata, providing a clinically translatable tool to identify inflamed plaques and to monitor therapy-mediated changes in plaque inflammation.
BACKGROUND: Macrophages contribute to the progression and acute complications of atherosclerosis. Macrophage imaging may serve as a biomarker to identify subclinical inflamed lesions, to predict future risk, and to aid in the assessment of novel therapies. METHODS AND RESULTS: To test the hypothesis that nanoparticle-enhanced, high-resolution magnetic resonance imaging (MRI) can measure plaque macrophage accumulation, we used 3-T MRI with a macrophage-targeted superparamagnetic nanoparticle preparation (monocrystalline iron oxide nanoparticles-47 [MION-47]) in cholesterol-fed New Zealand White rabbits 6 months after balloon injury. In vivo MRI visualized thickened abdominal aortas on both T1- and T2-weighted spin-echo images (T1 spin echo, 20 axial slices per animal; T2 spin echo, 28 slices per animal). Seventy-two hours after MION-47 injection, aortas exhibited lower T2 signal intensity compared with before contrast imaging (signal intensity ratio, aortic wall/muscle: before, 1.44 ± 0.26 versus after, 0.95 ± 0.22; 164 slices; P<0.01), whereas T1 spin echo images showed no significant change. MRI on ex vivo specimens provided similar results. Histological studies colocalized iron accumulation with immunoreactive macrophages in atheromata. The magnitude of signal intensity reduction on T2 spin echo in vivo images further correlated with macrophage areas in situ (150 slices; r=0.73). Treatment with rosuvastatin for 3 months yielded diminished macrophage content (P<0.05) and reversed T2 signal intensity changes (P<0.005). Signal changes in rosuvastatin-treated rabbits correlated with reduced macrophage burden (r=0.73). In vitro validation studies showed concentration-dependent MION-47 uptake by human primary macrophages. CONCLUSION: The magnitude of T2 signal intensity reduction in high-resolution MRI after administration of superparamagnetic phagocytosable nanoparticles can assess macrophage burden in atheromata, providing a clinically translatable tool to identify inflamed plaques and to monitor therapy-mediated changes in plaque inflammation.
Authors: Rikin A Trivedi; Chinthake Mallawarachi; Jean-Marie U-King-Im; Martin J Graves; Jo Horsley; Martin J Goddard; Andrew Brown; Liqun Wang; Peter J Kirkpatrick; John Brown; Jonathan H Gillard Journal: Arterioscler Thromb Vasc Biol Date: 2006-04-20 Impact factor: 8.311
Authors: David E Sosnovik; Matthias Nahrendorf; Nikolaos Deliolanis; Mikhail Novikov; Elena Aikawa; Lee Josephson; Anthony Rosenzweig; Ralph Weissleder; Vasilis Ntziachristos Journal: Circulation Date: 2007-03-05 Impact factor: 29.690
Authors: Elena Aikawa; Matthias Nahrendorf; David Sosnovik; Vincent M Lok; Farouc A Jaffer; Masanori Aikawa; Ralph Weissleder Journal: Circulation Date: 2007-01-15 Impact factor: 29.690
Authors: Jianming Cai; Thomas S Hatsukami; Marina S Ferguson; William S Kerwin; Tobias Saam; Baocheng Chu; Norihide Takaya; Nayak L Polissar; Chun Yuan Journal: Circulation Date: 2005-11-21 Impact factor: 29.690
Authors: C von Zur Muhlen; D von Elverfeldt; N Bassler; I Neudorfer; B Steitz; A Petri-Fink; H Hofmann; C Bode; K Peter Journal: Atherosclerosis Date: 2006-09-25 Impact factor: 5.162
Authors: Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2011-08-10
Authors: Jose J Rico-Jimenez; Michael J Serafino; Sebina Shrestha; Xi Chen; Wihan Kim; Jessie Adame; L Maximillan Buja; Deborah Vela; Brian E Applegate; Javier A Jo Journal: Atherosclerosis Date: 2019-04-19 Impact factor: 5.162
Authors: Seyedmehdi Hossaini Nasr; Anne Tonson; Mohammad H El-Dakdouki; David C Zhu; Dalen Agnew; Robert Wiseman; Chunqi Qian; Xuefei Huang Journal: ACS Appl Mater Interfaces Date: 2018-03-27 Impact factor: 9.229